Propanc Biopharma Inc.
PPCB
We prepare our consolidated financial statements in United States dollars and in accordance with generally accepted accounting principles as applied in the United States, ( U.S. Our novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$23M
▲ +68.0% YoY
Op. Margin
–
ROIC
-185.46%
▲ +461.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▼ -1303.8% YoY
Op. Cash Flow (TTM)
-$6M
▼ -1302.5% YoY
Net Debt
$149K
Cash & Equiv.
$258K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with PPCB
Propanc Biopharma (PPCB) in two numbers
Questions about Propanc Biopharma
Does Propanc Biopharma (PPCB) pay a dividend?
No. Propanc Biopharma (PPCB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PPCB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PPCB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.